Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

296.31
+0.55000.19%
Post-market: 295.02-1.2900-0.44%19:59 EDT
Volume:260.53K
Turnover:75.10M
Market Cap:570.24M
PE:- -
High:300.34
Open:290.97
Low:281.50
Close:295.76
52wk High:341.93
52wk Low:71.88
Shares:1.92M
Float Shares:1.92M
Volume Ratio:0.69
T/O Rate:13.54%
Dividend:1.01
Dividend Rate:0.34%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Ramsay Health Care (RMSYF) Receives a Hold from Citi

TIPRANKS
·
Aug 27

Sigma Healthcare-Chemist Warehouse Merger Delivers Strong First Full-Year Results

TIPRANKS
·
Aug 27

Ramsay Health Care Declares Interim Dividend of AUD 0.485 per Share

TIPRANKS
·
Aug 27

Health Care Down on Rotation Out of Biotech

Dow Jones
·
Aug 27

Vital Healthcare Property Trust Opens Director Nominations Ahead of November AGM

TIPRANKS
·
Aug 27

Health Care Roundup: Market Talk

Dow Jones
·
Aug 27

Revolution Medicines Earns Buy as RASONQUE FDA Approval and Strong Pricing Outlook Drive Price Target Increase to $315

TIPRANKS
·
Aug 27

FDA Grants Landmark Approval to Revolutionary Medicines' Pancreatic Cancer Therapy, Projected to Exceed $9 Billion in Sales by 2032

Deep News
·
Aug 27

FDA Approves Test to Identify Gastroesophageal Cancer Patients Eligible for Jazz Pharmaceuticals' Ziihera

MT Newswires Live
·
Aug 27

3 AI Healthcare Stocks Retail Investors Are Watching In Australia

Simply Wall St.
·
Aug 27

Sector Update: Healthcare

MT Newswires Live
·
Aug 27

Roche receives FDA approval for companion diagnostic tests for Ziihera

TIPRANKS
·
Aug 27

Analysts’ Top Healthcare Picks: CVS Health (CVS), TuHURA Biosciences (HURA)

TIPRANKS
·
Aug 27

Botanix Pharm: Strong Sofdra Adoption and Margin Upside Support Buy Rating with Unchanged $1 Price Target

TIPRANKS
·
Aug 27

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS) and Biohaven Ltd. (BHVN)

TIPRANKS
·
Aug 27

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

TIPRANKS
·
Aug 27

Revolution Medicines announces FDA approval of Rasonque in adults

TIPRANKS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

GlobeNewswire
·
Aug 27

GE Healthcare’s New Spectral CT Study: What Investors Should Watch

TIPRANKS
·
Aug 27

Worldwide Healthcare Trust Boosts Treasury Stock in Share Buyback

TIPRANKS
·
Aug 27